Evaluation value of serum FGFR4,HSP90α and OPN for short-term curative effect of neoadjuvant chemotherapy in patients with advanced cervical cancer
Objective:To explore the evaluation value of serum recombinant fibroblast growth factor receptor 4(FGFR4)combined with heat shock protein 90α(HSP90α)and osteopontin(OPN)for short-term curative effect of neoadjuvant chemotherapy in patients with advanced cervical cancer.Methods:The clinical data of 60 patients with advanced cervical cancer in the hospital between January 2023 and May 2024 were collected.All patients successfully underwent paclitaxel+carboplatin neoadjuvant chemotherapy for 3 cycles,and serum samples were collected before chemotherapy.According to short-term curative effect,patients were divided into effective group and ineffective group.The levels of FGFR4,HSP90α and OPN were compared between the two groups,and their predictive value for short-term curative effect of neoadjuvant chemotherapy was analyzed by receiver operating characteristic(ROC)curves.Results:Among 60 patients with advanced cervical cancer,there were 39 cases(65.00%)with effective treatment.The levels of serum FGFR4,HSP90α and OPN in effective group were lower than those in ineffective group(P<0.05).The results of ROC curves analysis showed that area under the curve(AUC)values of FGFR4,HSP90α,OPN and combined detection for predicting short-term curative effect of neoadjuvant chemotherapy were 0.793,0.713,0.803 and 0.923,all showing certain predictive value(P<0.05).Conclusion:FGFR4,HSP90α and OPN all have certain predictive value for short-term curative effect of neoadjuvant chemotherapy in patients with advanced cervical cancer,and combined detection has higher predictive efficiency.
Fibroblast growth factor receptor 4Heat shock protein 90αOsteopontinAdvanced cervical cancerShort-term curative effect of neoadjuvant chemotherapy
NETL
NSTL
万方数据
